Jul. 27, 2022

apararenone

oral nonsteroidal MR antagonist Ph. II candidate in DN and NASH (discontinued) previous literature and hypothesis-driven opt. J. Med. Chem. Mitsubishi Tanabe Pharma Corporation, Yokohama, JP

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in